



September 2019

MMR II Vaccine (Measles, mumps and rubella vaccine)

Supply of Singapore-labelled MMR II to New Zealand

Dear Health Professional,

This communication is intended for Healthcare Professionals (HCPs) who perform the administration of the MMR II Vaccine to patients.

Summary

MSD is supplying the following batch of Singapore-labelled MMR II Vaccine to the New Zealand market upon request from PHARMAC to address the measles outbreak in New Zealand:

Batch Number: S021856
Expiry Date: 16-July 2021

Please note the following:

Comparison of Singapore and New Zealand label

A side-by-side comparison of the Singapore and New Zealand labels (vaccine carton, vaccine vial label, diluent vial label, package insert) are appended to this letter.

New Zealand Data Sheet and CMI

The New Zealand Data Sheet and Consumer Medicine Information for MMR II may be accessed at www.medsafe.govt.nz

Classification and dosage form

The classification 'Prescription Medicine' and the dosage form 'Powder for injection with diluent' are not present on the Singapore product.

Excipients

The following excipients, which are present in the New Zealand product, are also present in the Singapore product:

Dibasic potassium phosphate
Dibasic sodium phosphate
Monobasic potassium phosphate
Monobasic sodium phosphate
Monosodium glutamate monohydrate
Phenolsulfonphthalein
Sodium bicarbonate
Sorbitol
Sucrose
Hydrolysed gelatin
Neomycin
Other buffer and media ingredients

Storage condition

The Medsafe-approved instructions for storage must be followed:

Store at 2-8 °C. (REFRIGERATE. DO NOT FREEZE.) Protect from light.

Pregnancy Warning

The Medsafe-approved pregnancy warning must be followed:

WARNING: NOT TO BE ADMINISTERED TO PREGNANT WOMEN. A woman must not become pregnant within 3 months after having the vaccine.

Adverse Event, Product Quality Complaint reporting and Company Contact Point

If you have any questions regarding MMR II or if you wish to report any suspected Adverse Events and/or Product Quality Complaints with the use of MMR II to MSD:

Email: dpoc.australia@merck.com
T: 0800 500 673

Yours faithfully,



Chad Woodcock
NZ Medical Director

